{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:04:25Z","timestamp":1792271065157,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejim.2026.107156","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:35:58Z","timestamp":1787574958000},"page":"107156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Steroid-sparing biologics in severe asthma and chronic obstructive pulmonary disease: a systematic review, cross-disease meta-analysis, and translational estimate of corticosteroid-related harm prevented"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3307-217X","authenticated-orcid":false,"given":"Pier-Valerio","family":"Mari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2538-1278","authenticated-orcid":false,"given":"Lorenzo","family":"Carriera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Onofrio","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2838-423X","authenticated-orcid":false,"given":"Simone","family":"Ielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1718-1587","authenticated-orcid":false,"given":"Alberto","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Ojetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-8629","authenticated-orcid":false,"given":"Umberto","family":"Semenzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3950-5789","authenticated-orcid":false,"given":"Francesco","family":"Menzella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Baglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Becattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"De Corso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2026.107156_bib0002","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2025 report. Available from: https:\/\/goldcopd.org (Accessed March 2026)."},{"key":"10.1016\/j.ejim.2026.107156_bib0003","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"issue":"1","key":"10.1016\/j.ejim.2026.107156_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ejim.2026.107156_bib0005","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejim.2026.107156_bib0006","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12931-018-0742-y","article-title":"Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis","volume":"19","author":"Bloechliger","year":"2018","journal-title":"Respir Res"},{"issue":"12","key":"10.1016\/j.ejim.2026.107156_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.ejim.2026.107156_bib0008","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1210\/jc.2019-00153","article-title":"Dose dependency of iatrogenic glucocorticoid excess and adrenal insufficiency and mortality: a cohort study in England","volume":"104","author":"Mebrahtu","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2026.107156_bib0009","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-2600(26)00118-9","article-title":"Is the SUNRISE study a new dawn in steroid stewardship?","volume":"14","author":"Ko","year":"2026","journal-title":"Lancet Respir Med"},{"issue":"13","key":"10.1016\/j.ejim.2026.107156_bib0010","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma (SIRIUS)","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ejim.2026.107156_bib0011","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma (ZONDA)","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejim.2026.107156_bib0012","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma (VENTURE)","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejim.2026.107156_bib0013","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S2213-2600(26)00076-7","article-title":"Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial","volume":"14","author":"Wechsler","year":"2026","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.ejim.2026.107156_bib0014","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts (BOREAS)","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ejim.2026.107156_bib0015","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation (NOTUS)","volume":"390","author":"Bhatt","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejim.2026.107156_bib0016","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S2213-2600(24)00409-0","article-title":"Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials (BOREAS and NOTUS)","volume":"13","author":"Bhatt","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"10543","key":"10.1016\/j.ejim.2026.107156_bib0017","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(26)00637-9","article-title":"Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials","volume":"407","author":"Papi","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2026.107156_bib0018","article-title":"Astegolimab for COPD with frequent exacerbations: Pooled analysis of the ALIENTO and ARNASA trials","author":"Wedzicha","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejim.2026.107156_bib0019","article-title":"Dupilumab in COPD: A pooled analysis of emergency department visits, hospital admissions, and systemic corticosteroid use","author":"Bhatt","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ejim.2026.107156_bib0020","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaip.2023.11.007","article-title":"Efficacy and safety of biologics for oral corticosteroid-dependent asthma: a systematic review and network meta-analysis","volume":"12","author":"Phinyo","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ejim.2026.107156_bib0021","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.2147\/COPD.S550144","article-title":"Multi-criteria decision analysis of biologics in chronic obstructive pulmonary disease","volume":"20","author":"Matera","year":"2025","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"6","key":"10.1016\/j.ejim.2026.107156_bib0022","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40265-026-02310-4","article-title":"Current and emerging biologic therapies for severe asthma","volume":"86","author":"Cazzola","year":"2026","journal-title":"Drugs"},{"key":"10.1016\/j.ejim.2026.107156_bib0023","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2026.107156_bib0024","unstructured":"Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., et al, editor(s). Cochrane handbook for systematic reviews of interventions version 6.5 (updated August 2024). Cochrane, 2024. Available from www.cochrane.org\/handbook."},{"issue":"7","key":"10.1016\/j.ejim.2026.107156_bib0025","first-page":"816","article-title":"Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review","volume":"50","author":"Bourdin","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"13","key":"10.1016\/j.ejim.2026.107156_bib0026","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.3390\/ijms22137132","article-title":"Oral corticosteroid-sparing effect of biological therapies in severe asthma: a systematic review of real-world evidence","volume":"22","author":"Calzetta","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10516","key":"10.1016\/j.ejim.2026.107156_bib0027","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/S0140-6736(25)01625-3","article-title":"Anti-cytokine biologics for asthma in adults","volume":"406","author":"Israel","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2026.107156_bib0028","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.ejim.2026.107156_bib0029","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ejim.2026.107156_bib0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"1","key":"10.1016\/j.ejim.2026.107156_bib0031","doi-asserted-by":"crossref","first-page":"00172","DOI":"10.1183\/23120541.00172-2024","article-title":"Systemic corticosteroid dose-response effects in asthma: an observational cohort study","volume":"11","author":"Xu","year":"2025","journal-title":"ERJ Open Res"},{"issue":"17","key":"10.1016\/j.ejim.2026.107156_bib0032","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype (MATINEE)","volume":"392","author":"Sciurba","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejim.2026.107156_bib0033","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-2600(25)00359-5","article-title":"Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial","volume":"14","author":"Jackson","year":"2026","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.107156_bib0034","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE)","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"19","key":"10.1016\/j.ejim.2026.107156_bib0035","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma (NAVIGATOR)","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ejim.2026.107156_bib0036","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype (SWIFT-1 and SWIFT-2)","volume":"391","author":"Jackson","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejim.2026.107156_bib0037","first-page":"921","article-title":"Switching to twice-yearly depemokimab from mepolizumab or benralizumab in severe asthma: a multicentre, randomised, double-blind, phase 3A clinical trial (NIMBLE)","volume":"212","author":"Chupp","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"issue":"17","key":"10.1016\/j.ejim.2026.107156_bib0038","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease (METREX and METREO)","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejim.2026.107156_bib0039","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations (GALATHEA and TERRANOVA)","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.107156_bib0040","doi-asserted-by":"crossref","first-page":"2402231","DOI":"10.1183\/13993003.02231-2024","article-title":"A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4","volume":"66","author":"Singh","year":"2025","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.ejim.2026.107156_bib0041","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE)","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.ejim.2026.107156_bib0042","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejim.2026.107156_bib0043","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines14081675","article-title":"COPD stability and asthma remission: different words for the same therapeutic ambition?","volume":"14","author":"Carriera","year":"2026","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.ejim.2026.107156_bib0044","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults","volume":"210","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"9976","key":"10.1016\/j.ejim.2026.107156_bib0045","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"issue":"10022","key":"10.1016\/j.ejim.2026.107156_bib0046","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejim.2026.107156_bib0047","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF)","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.107156_bib0048","article-title":"Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations","volume":"13","author":"Watz","year":"2026","journal-title":"BMJ Open Respir Res"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526004619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526004619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:36:04Z","timestamp":1787574964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526004619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":47,"alternative-id":["S0953620526004619"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107156","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Steroid-sparing biologics in severe asthma and chronic obstructive pulmonary disease: a systematic review, cross-disease meta-analysis, and translational estimate of corticosteroid-related harm prevented","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"107156"}}